Literature DB >> 25036923

An in vitro culture model to study the dynamics of colonic microbiota in Syrian golden hamsters and their susceptibility to infection with Clostridium difficile.

Matthew Miezeiewski1, Todd Schnaufer2, Michele Muravsky2, Su Wang2, Ivette Caro-Aguilar2, Susan Secore2, David S Thiriot2, Charlie Hsu2, Irene Rogers2, Todd DeSantis3, Justin Kuczynski3, Alexander J Probst3, Christel Chehoud3, Rachel Steger4, Janet Warrington4, Jean-Luc Bodmer2, Jon H Heinrichs2.   

Abstract

Clostridium difficile infections (CDI) are caused by colonization and growth of toxigenic strains of C. difficile in individuals whose intestinal microbiota has been perturbed, in most cases following antimicrobial therapy. Determination of the protective commensal gut community members could inform the development of treatments for CDI. Here, we utilized the lethal enterocolitis model in Syrian golden hamsters to analyze the microbiota disruption and recovery along a 20-day period following a single dose of clindamycin on day 0, inducing in vivo susceptibility to C. difficile infection. To determine susceptibility in vitro, spores of strain VPI 10463 were cultured with and without soluble hamster fecal filtrates and growth was quantified by quantitative PCR and toxin immunoassay. Fecal microbial population changes over time were tracked by 16S ribosomal RNA gene analysis via V4 sequencing and the PhyloChip assay. C. difficile culture growth and toxin production were inhibited by the presence of fecal extracts from untreated hamsters but not extracts collected 5 days post-administration of clindamycin. In vitro inhibition was re-established by day 15, which correlated with resistance of animals to lethal challenge. A substantial fecal microbiota shift in hamsters treated with antibiotics was observed, marked by significant changes across multiple phyla including Bacteroidetes and Proteobacteria. An incomplete return towards the baseline microbiome occurred by day 15 correlating with the inhibition of C. difficile growth in vitro and in vivo. These data suggest that soluble factors produced by the gut microbiota may be responsible for the suppression of C. difficile growth and toxin production.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25036923      PMCID: PMC4303626          DOI: 10.1038/ismej.2014.127

Source DB:  PubMed          Journal:  ISME J        ISSN: 1751-7362            Impact factor:   10.302


  36 in total

1.  Method for removal of vegetative cells from Bacterial spore preparations.

Authors:  S K LONG; O B WILLIAMS
Journal:  J Bacteriol       Date:  1958-09       Impact factor: 3.490

2.  Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB.

Authors:  T Z DeSantis; P Hugenholtz; N Larsen; M Rojas; E L Brodie; K Keller; T Huber; D Dalevi; P Hu; G L Andersen
Journal:  Appl Environ Microbiol       Date:  2006-07       Impact factor: 4.792

Review 3.  Bile salt biotransformations by human intestinal bacteria.

Authors:  Jason M Ridlon; Dae-Joong Kang; Phillip B Hylemon
Journal:  J Lipid Res       Date:  2005-11-18       Impact factor: 5.922

4.  Effect of clindamycin given alone or with Lactobacillus delbrueckii and Streptococcus thermophilus on 7alpha-dehydroxylation of bile acids in rats.

Authors:  Aina Gustafsson; Elisabeth Norin; Tore Midtvedt
Journal:  Clin Microbiol Infect       Date:  1998       Impact factor: 8.067

5.  Characterization of the fecal microbiome from non-human wild primates reveals species specific microbial communities.

Authors:  Suleyman Yildirim; Carl J Yeoman; Maksim Sipos; Manolito Torralba; Brenda A Wilson; Tony L Goldberg; Rebecca M Stumpf; Steven R Leigh; Bryan A White; Karen E Nelson
Journal:  PLoS One       Date:  2010-11-12       Impact factor: 3.240

6.  Bile acid metabolism by fresh human colonic contents: a comparison of caecal versus faecal samples.

Authors:  L A Thomas; M J Veysey; G French; P B Hylemon; G M Murphy; R H Dowling
Journal:  Gut       Date:  2001-12       Impact factor: 23.059

7.  Duodenal infusion of donor feces for recurrent Clostridium difficile.

Authors:  Els van Nood; Anne Vrieze; Max Nieuwdorp; Susana Fuentes; Erwin G Zoetendal; Willem M de Vos; Caroline E Visser; Ed J Kuijper; Joep F W M Bartelsman; Jan G P Tijssen; Peter Speelman; Marcel G W Dijkgraaf; Josbert J Keller
Journal:  N Engl J Med       Date:  2013-01-16       Impact factor: 91.245

8.  Cofactor requiremets for 7 alpha-dehydroxylation of cholic and chenodeoxycholic acid in cell extracts of the intestinal anaerobic bacterium, Eubacterium species V.P.I. 13708.

Authors:  B A White; A F Cacciapuoti; R J Fricke; T R Whitehead; E H Mosbach; P B Hylemon
Journal:  J Lipid Res       Date:  1981-08       Impact factor: 5.922

Review 9.  Clostridium difficile infection: new developments in epidemiology and pathogenesis.

Authors:  Maja Rupnik; Mark H Wilcox; Dale N Gerding
Journal:  Nat Rev Microbiol       Date:  2009-07       Impact factor: 60.633

10.  Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole.

Authors:  Turki Abujamel; Jennifer L Cadnum; Lucy A Jury; Venkata C K Sunkesula; Sirisha Kundrapu; Robin L Jump; Alain C Stintzi; Curtis J Donskey
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

View more
  11 in total

Review 1.  Engineering the microbiome for animal health and conservation.

Authors:  Se Jin Song; Douglas C Woodhams; Cameron Martino; Celeste Allaband; Andre Mu; Sandrine Javorschi-Miller-Montgomery; Jan S Suchodolski; Rob Knight
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-18

2.  Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.

Authors:  Peter Warn; Pia Thommes; Abdul Sattar; David Corbett; Amy Flattery; Zuo Zhang; Todd Black; Lorraine D Hernandez; Alex G Therien
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

3.  IL-17 Receptor A Maintains and Protects the Skin Barrier To Prevent Allergic Skin Inflammation.

Authors:  Achilleas Floudas; Sean P Saunders; Tara Moran; Christian Schwartz; Emily Hams; Denise C Fitzgerald; James A Johnston; Graham S Ogg; Andrew N McKenzie; Patrick T Walsh; Padraic G Fallon
Journal:  J Immunol       Date:  2017-06-14       Impact factor: 5.422

4.  New perspectives on microbial community distortion after whole-genome amplification.

Authors:  Alexander J Probst; Thomas Weinmaier; Todd Z DeSantis; Jorge W Santo Domingo; Nicholas Ashbolt
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

5.  Disease-induced assemblage of a plant-beneficial bacterial consortium.

Authors:  Roeland L Berendsen; Gilles Vismans; Ke Yu; Yang Song; Ronnie de Jonge; Wilco P Burgman; Mette Burmølle; Jakob Herschend; Peter A H M Bakker; Corné M J Pieterse
Journal:  ISME J       Date:  2018-03-08       Impact factor: 10.302

6.  Spontaneous atopic dermatitis in mice with a defective skin barrier is independent of ILC2 and mediated by IL-1β.

Authors:  Christian Schwartz; Tara Moran; Sean P Saunders; Agnieszka Kaszlikowska; Achilleas Floudas; Joana Bom; Gabriel Nunez; Yoichiro Iwakura; Luke O'Neill; Alan D Irvine; Andrew N J McKenzie; Graham Ogg; Patrick T Walsh; Jocelyne Demengeot; Padraic G Fallon
Journal:  Allergy       Date:  2019-04-29       Impact factor: 13.146

7.  Bacterial and Fungal Microbiota Changes Distinguish C. difficile Infection from Other Forms of Diarrhea: Results of a Prospective Inpatient Study.

Authors:  William Sangster; John P Hegarty; Kathleen M Schieffer; Justin R Wright; Jada Hackman; David R Toole; Regina Lamendella; David B Stewart
Journal:  Front Microbiol       Date:  2016-05-25       Impact factor: 5.640

8.  Nasopharyngeal microbiota composition of children is related to the frequency of upper respiratory infection and acute sinusitis.

Authors:  Clark A Santee; Nabeetha A Nagalingam; Ali A Faruqi; Gregory P DeMuri; James E Gern; Ellen R Wald; Susan V Lynch
Journal:  Microbiome       Date:  2016-07-01       Impact factor: 14.650

9.  A High-Fat/High-Protein, Atkins-Type Diet Exacerbates Clostridioides (Clostridium) difficile Infection in Mice, whereas a High-Carbohydrate Diet Protects.

Authors:  Chrisabelle C Mefferd; Shrikant S Bhute; Jacqueline R Phan; Jacob V Villarama; Dung M Do; Stephanie Alarcia; Ernesto Abel-Santos; Brian P Hedlund
Journal:  mSystems       Date:  2020-02-11       Impact factor: 6.496

10.  Cervical Microbiome and Response to a Human Papillomavirus Therapeutic Vaccine for Treating High-Grade Cervical Squamous Intraepithelial Lesion.

Authors:  Rahul Ravilla; Hannah N Coleman; Cheryl-Emiliane Chow; Luisa Chan; Barbara J Fuhrman; William W Greenfield; Michael Scott Robeson; Kathryn Iverson; Horace Spencer; Mayumi Nakagawa
Journal:  Integr Cancer Ther       Date:  2019 Jan-Dec       Impact factor: 3.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.